O recente crescimento da utilização de Unidades de Processamento Gráfico (GPUs) em aplicações científicas, que são voltadas ao desempenho, gerou a necessidade de otimizar os programas que nelas rodam. Uma ferramenta adequada para essa tarefa é o modelo de desempenho que, por sua vez, se beneficia da existência de uma ferramenta de extração de informações de desempenho para GPUs. Este trabalho cobre a criação de um gerador de microbenchmark para instruções PTX que também obtém informações sobre as características do hardware da GPU. Os resultados obtidos com o microbenchmark foram validados através de um modelo simplificado que obteve erros entre 6,11% e 16,32% em cinco kernels de teste. Também foram levantados os fatores de imprecisão nos resultados do microbenchmark. Utilizamos a ferramenta para analisar o perfil de desempenho das instruções e identificar grupos de comportamentos semelhantes. Também testamos a dependência do desempenho do pipeline da GPU em função da sequência de instruções executada e verificamos a otimização do compilador para esse caso. Ao fim deste trabalho concluímos que a utilização de microbenchmarks com instruções PTX é factível e se mostrou eficaz para a construção de modelos e análise detalhada do comportamento das instruções. / The recent growth in the use of tailored for performance Graphics Processing Units (GPUs) in scientific applications, generated the need to optimize GPU targeted programs. Performance models are the suitable tools for this task and they benefits from existing GPUs performance information extraction tools. This work covers the creation of a microbenchmark generator using PTX instructions and it also retrieves information about the GPU hardware characteristics. The microbenchmark results were validated using a simplified model with errors rates between 6.11% and 16.32% under five diferent GPU kernels. We also explain the imprecision factors present in the microbenchmark results. This tool was used to analyze the instructions performance profile, identifying groups with similar behavior. We also evaluated the corelation of the GPU pipeline performance and instructions execution sequence. Compiler optimization capabilities for this case were also verified. We concluded that the use of microbenchmarks with PTX instructions is a feasible approach and an efective way to build performance models and to generate detailed analysis of the instructions\' behavior.

O recente crescimento da utilização de Unidades de Processamento Gráfico (GPUs) em aplicações científicas, que são voltadas ao desempenho, gerou a necessidade de otimizar os programas que nelas rodam. Uma ferramenta adequada para essa tarefa é o modelo de desempenho que, por sua vez, se beneficia da existência de uma ferramenta de extração de informações de desempenho para GPUs. Este trabalho cobre a criação de um gerador de microbenchmark para instruções PTX que também obtém informações sobre as características do hardware da GPU. Os resultados obtidos com o microbenchmark foram validados através de um modelo simplificado que obteve erros entre 6,11% e 16,32% em cinco kernels de teste. Também foram levantados os fatores de imprecisão nos resultados do microbenchmark. Utilizamos a ferramenta para analisar o perfil de desempenho das instruções e identificar grupos de comportamentos semelhantes. Também testamos a dependência do desempenho do pipeline da GPU em função da sequência de instruções executada e verificamos a otimização do compilador para esse caso. Ao fim deste trabalho concluímos que a utilização de microbenchmarks com instruções PTX é factível e se mostrou eficaz para a construção de modelos e análise detalhada do comportamento das instruções. / The recent growth in the use of tailored for performance Graphics Processing Units (GPUs) in scientific applications, generated the need to optimize GPU targeted programs. Performance models are the suitable tools for this task and they benefits from existing GPUs performance information extraction tools. This work covers the creation of a microbenchmark generator using PTX instructions and it also retrieves information about the GPU hardware characteristics. The microbenchmark results were validated using a simplified model with errors rates between 6.11% and 16.32% under five diferent GPU kernels. We also explain the imprecision factors present in the microbenchmark results. This tool was used to analyze the instructions performance profile, identifying groups with similar behavior. We also evaluated the corelation of the GPU pipeline performance and instructions execution sequence. Compiler optimization capabilities for this case were also verified. We concluded that the use of microbenchmarks with PTX instructions is a feasible approach and an efective way to build performance models and to generate detailed analysis of the instructions\' behavior.

Pectenotoxins (PTXs) are a group of large cyclic polyether compounds associated with diarrhetic shellfish poisoning (DSP) as they are often found in combination with other DSPs such as okadaic acid (OA) and dinophysis toxins (DTXs) in shellfish. Although classified and regulated with the DSPs, there is debate over whether these toxins should be classified with DSP toxins. To date, ten different analogues of PTXs have been identified from shellfish and algae, and of these, the pectenotoxin-2 seco acids (PTX2-SAs) are of particular interest as they have previously been implicated in a shellfish poisoning incident in Australia, but relatively little was known of their toxicology. One such incident occurred in December 1997, when approximately 200 people were reported with severe diarrhoetic shellfish poisoning in Northern New South Wales (NSW). Analysis of the shellfish associated with this incident revealed relatively high PTX2-SA concentrations (approx. 300 micrograms/kg shellfish meat), with only trace amounts of pectenotoxin-2 (PTX2) and OA. Following this incident, PTX2-SAs were considered a health threat and guidelines were implemented in the absence of toxicological data, which has caused a great economic burden to shellfish industries around the globe, in particular to Australia, New Zealand and Ireland. Such regulation created in the absence of scientific data demonstrated the need to determine the toxicology of PTX2-SAs in commercial shellfish. Thus a comprehensive study on the toxicology and possible health implications of the PTX2-SAs in Australian shellfish was conducted. PTX2-SAs were isolated in different batches from shellfish (pipis, oysters and mussels) and from algal bloom samples of Dinophysis caudata. Toxin extraction was conducted with several purification stages and chemical analysis was performed with high-performance liquid chromatography coupled to a tandem mass spectrometer (HPLC-MS/MS). The chemical stability of the PTX2-SAs was investigated to ensure consistency of doses between toxicology experiments. Acute dosing studies with mice were then performed and included toxicopathology investigations with light microscopy and electron microscopy, in addition to toxin distribution studies and investigation of in vivo lipid peroxidation. In vitro studies with HepG2 cells included cytotoxicity assays, cell cycle investigations using flow cytometry and gene expression profiling of cells exposed to PTX2-SAs employing cDNA microarray technology. Acute pathology studies demonstrated that the PTX2-SAs do not cause the characteristic symptoms or lesions associated with DSP toxins. No diarrhoea was observed at any dose level in mice and no deaths occurred up to the maximum dosing level of 1.6mg/kg PTX2-SA. Only one batch of PTX2-SA extract produced toxic lesions characteristic of a DSP toxin (batch 1-pilot study) but after follow up studies, it was determined that this first batch of shellfish most likely contained an additional unidentified shellfish toxin or contaminant that co-extracted with PTX2-SAs during toxin isolation and purification procedures. This finding highlighted the importance of supporting the inclusion of the mice bioassay in procedures for shellfish toxin testing to enable detection of new toxins, and also highlighted the importance of toxin purification for toxicology studies. A significant rise in malondialdehyde excretion was observed within 24 hours of dosing mice, indicating that the PTX2-SAs may cause damage by lipid peroxidation in vivo. In vitro studies showed HepG2 cells to have cell cycle and gene expression changes within 24 hours of a dose of 800ng/mL PTX2-SAs. Cell cycle arrest was observed at the G2/M checkpoint and gene expression changes included alterations in genes involved in cell cycle control, lipid metabolism and transport, lipid genesis and trace metal transport. Many genes involved in DNA repair processes were moderated at the 24 hour point, but as no apoptosis was observed up to 72 hours post dosing it is a promising indication that any DNA damage that may have been caused by the administration of PTX2-SAs was not lethal, and was able to be repaired. In light of the information provided by toxicology investigations in this PhD, with particular reference to evidence of in vivo lipid peroxidation by raised levels of MDA in mouse urine, and changes in cell cycle distribution and gene expression in a cultured human cell line, it is concluded that there is potential for these toxins to induce biological changes in mammalian cells in vivo and in vitro, and hence potential for PTX2-SAs to cause health effects in humans. During the course of this three-year study, developments in techniques for shellfish toxin identification within our laboratories have revealed that the shellfish responsible for the 1997 NSW poisoning incident contained significant concentrations of okadaic acid acyl esters that were not detected at the time of the NSW incident. Although reportedly less toxic than okadaic acid itself, the OA ester concentrations present may have been sufficient to cause the observed symptoms. It is also theorized that these esters could be hydrolyzed in the human gastro-intestinal tract to release okadaic acid. In the light of this new evidence and with no pathology lesions or symptoms of diarrhoea being observed in PTX2-SA dosing studies with mice, we now believe these OA acyl esters to be the causative agent in the 1997 NSW DSP incident and not the PTX2-SAs. Nothing is currently known of the chronic toxicology of PTX2-SAs and thus their potential implications to public health in the long term cannot determined. The toxicology investigations in this thesis were acute studies, and it has not been established if the observed changes could be repaired or returned within normal limits without the manifestation of illness or disease occurring. Utilizing the acute toxicology information in this thesis, a health risk assessment for consumption of PTX2-SA contaminated shellfish was performed. This risk assessment, employing numerous safety factors essential for an incomplete data set, produced guideline values that are lower than the current recommend concentrations. To date, there has been no solid evidence that PTX2-SAs cause illness in humans – all documented incidents involving the PTX2-SAs have also included other DSP contaminants that are known to cause human illness. Pathology has not unequivocally been demonstrated in animal studies and thus, in consideration of the epidemiological evidence, PTX2-SAs cannot be considered as high a risk to public health as was previously thought. For the reasons discussed above, and weighing up risk-benefit considerations of the economic burden the current guideline values are causing to shellfish industries around the globe, it is recommended that levels of PTX2-SAs be monitored in recognition of the precautionary principle, but no longer regulated as tightly with other DSPs until such a time that toxicological or epidemiological evidence can prove that the PTX2-SAs are a DSP and are a more considerable threat to human health than has been indicated by toxicology studies in this thesis. This study has produced a substantial amount of acute toxicology data and has provided a good basis for future chronic toxicology investigations with the PTX2-SAs for regulatory purposes.

<p>The recent FDA regulatory clearance for the 7 tesla Magnetic Resonance Imaging (MRI) system has led to increased interest in clinical ultra-high field (UHF) applications. However, to robustly achieve the expected increase in signal-to-noise ratio (SNR) at UHF, the radiofrequency (RF) challenges need to be met, namely, problems with higher RF power, worse <i>B₁⁺</i> inhomogeneity (signal voids) and increased tissue dielectric properties at higher frequency, all of which usually results in increased specific absorption rate (SAR). The parallel transmission (pTx) techniques are generally accepted as a realistic solution, providing improvement in the <i>B₁⁺</i> homogeneity with good RF efficiency while reducing peak local SAR. We designed a hybrid circuit-spatial domain optimization to accelerate the design of a double row pTx head coil. The method predicted consistent coil scattering parameters, component values and <i>B₁⁺</i> field. RF shimming of the calculated field maps matched in vivo performance. To further increase the <i>B₁⁺</i> homogeneity in tissue, we added high dielectric material (HPM) pads near the coil, as the displacement currents in the HPM induced secondary <i>B₁⁺</i> in tissue. This raises a RF safety question of how to monitor millions of local SAR (complex valued Q-matrix) in the tissue voxels, for any weightings (forward voltages) applied to the pTx system. We implemented VOPs based on singular value decomposition to compress the Q-matrices with a compression ratio >100, effectively monitoring the maximum peak local SAR values at given weighting amplitudes.</p>

La toxine de pertussis (PTX) est une A-B protéine considérée comme l’un des principaux facteurs de virulence de Bordetella pertussis, l’agent bactérien responsable de la coqueluche. Aujourd’hui, cette maladie représente encore un réel danger pour les nouveaux-nés et les nourrissons non ou partiellement immunisés. Actuellement, la coqueluche provoque encore la mort d’environ 350.000 individus par an. La toxicité de la PTX est liée à l’activité enzymatique de sa sous-unité A capable d’inhiber les voies de signalisation associées aux protéines Gi. La partie B, quant à elle, permet l’entrée de cette sous-unité A dans le cytoplasme des cellules cibles en se liant spécifiquement à son ou ses récepteurs membranaires toujours inconnus de nos jours. Des études réalisées chez la souris et chez l’homme ont montré que les vaccins anticoquelucheux combinés à différents antigènes vaccinaux étaient capables de moduler leurs réponses humorales spécifiques. Par ailleurs, la PTX est couramment qualifiée d’agent immunostimulant. En effet, des modèles murins de vaccination permirent d’identifier des propriétés adjuvantes de la PTX coadministrée avec des antigènes non relevants. Le travail développé dans ce manuscrit étudie les effets de la PTX sur 2 types cellulaires primordiaux sollicités lors d’une vaccination : la cellule dendritique (DC) et le lymphocyte T CD4+ naïf. Les DC sont les seules cellules présentatrices d’antigènes aptes à initier une réponse immune primaire. Dans un premier temps, nous avons montré que la PTX était capable d’activer des DC générées in vitro à partir de monocytes. En effet, elles acquièrent un phénotype mature caractérisé par une augmentation de l’expression membranaire des molécules costimulatrices et du CMH de classe II, démontrant un effet direct et spécifique de la PTX sur les DC myéloïdes. Parallèlement, ces DC produisent du TNF-a, de l’IL-12p40 et de l’IL-12p70 et activent NF-kappaB, un facteur de transcription essentiel au processus de maturation. Nous avons obtenu des résultats similaires avec une toxine génétiquement modifiée qui est enzymatiquement inactive. A partir de sang total incubé avec la PTX, nous avons par ailleurs observé que les DC circulantes du nouveau-né étaient déficientes dans leur maturation et leur sécrétion d’IL-12p70 comparées aux DC de l’adulte. D’autre part, il a été décrit précédemment que la PTX exerçait des effets mitogènes sur les lymphocytes T humains et murins. Cependant, le rôle qu’elle joue sur la population des lymphocytes T CD4 naïfs reste peu connu. A l’issue de notre second travail, nous pouvons dès lors affirmer que la PTX est également capable d’activer des lymphocytes T CD4+CD45RA+ naïfs isolés à partir des cellules mononuclées du sang périphérique, et ce indépendamment de son activité enzymatique. En effet, ces lymphocytes T CD4+ naïfs stimulés par la PTX prolifèrent, synthétisent des quantités non négligeables d'ARN messagers codant pour l’IL-2 et le TNF-a, augmentent l’expression membranaire des molécules CD40L, CD69 et CD25 et expriment la protéine Foxp3. Cette activation s’accompagne de la translocation nucléaire de NF-kappaB et NFAT. Parallèlement à l’adulte, la PTX active les lymphocytes T CD4 néonataux. Néanmoins, ceux-ci prolifèrent moins bien et expriment plus faiblement le CD40L à leur surface. Enfin, la PTX induit la sécrétion de taux importants d’IFN-g par des T CD4+CD45RA+ naïfs adultes mis en présence de DC autologues. Nous terminerons en proposant l’hypothèse suivante : La PTX pourrait exercer ses propriétés adjuvantes par l’intermédiaire de différents mécanismes comprenant notamment la maturation des DC d’origine myéloïde et l’activation des lymphocytes T CD4+CD45RA+ naïfs. Ces 2 populations cellulaires sont en effet les principaux protagonistes impliqués dans la réponse immune primaire.

In many geologic environments, fluids have compositions that are approximated by the H₂O-NaCl system. When minerals grow in the presence of such fluids, some of the solution is trapped in the growing mineral as fluid inclusions. The salinity, temperature of homogenization, and pressure of homogenization are required to predict the trapping conditions of the fluid inclusion. In the laboratory the salinity and the temperature of homogenization of the trapped fluid are easily determined however, the pressure of homogenization cannot be determined directly, and must be calculated from an equation of state. A statistical model that relates the vapor pressure of H₂O-NaCl to the fluid temperature and composition has been developed. The model consists of equations that predict the vapor pressure of H₂O-NaCl from the eutectic temperature (-21.2°C) to 1500°C and for all compositions between the pure end-members. The model calculates the vapor pressure based on the composition (wt% NaCl) and the temperature of homogenization, which can be directly obtained from laboratory studies of fluid inclusions. This information in turn can be used to construct the isochore, or line of constant volume, along which the fluid inclusion was trapped. Finally the isochore can be used to determine the temperature and pressure at which the host mineral of the fluid inclusion was trapped. / Master of Science

Parmi l’ensemble des désordres métaboliques retrouvés en insuffisance rénale chronique (IRC), la résistance à l’insuline demeure l’un des plus importantes à considérer en raison des risques de morbidité et de mortalité qu’elle engendre via les complications cardiovasculaires. Peu d’études ont considéré la modulation de transporteurs de glucose comme mécanisme sous-jacent à l’apparition et à la progression de la résistance à l’insuline en IRC. Nous avons exploré cette hypothèse en étudiant l’expression de transporteurs de glucose issus d’organes impliqués dans son homéostasie (muscles, tissus adipeux, foie et reins) via l’utilisation d’un modèle animal d’IRC (néphrectomie 5/6e). La sensibilité à l’insuline a été déterminée par un test de tolérance au glucose (GTT), où les résultats reflètent une intolérance au glucose et une hyperinsulinémie, et par les études de transport au niveau musculaire qui témoignent d’une diminution du métabolisme du glucose en IRC (~31%; p<0,05). La diminution significative du GLUT4 dans les tissus périphériques (~40%; p<0,001) peut être à l’origine de la résistance à l’insuline en IRC. De plus, l’augmentation de l’expression protéique de la majorité des transporteurs de glucose (SGLT1, SGLT2, GLUT1; p<0,05) au niveau rénal en IRC engendre une plus grande réabsorption de glucose dont l’hyperglycémie subséquente favorise une diminution du GLUT4 exacerbant ainsi la résistance à l’insuline. L’élévation des niveaux protéiques de GLUT1 et GLUT2 au niveau hépatique témoigne d’un défaut homéostatique du glucose en IRC. Les résultats jusqu’ici démontrent que la modulation de l’expression des transporteurs de glucose peut être à l’origine de la résistance à l’insuline en IRC. L’impact de la parathyroïdectomie (PTX) sur l’expression du GLUT4 a été étudié étant donné que la PTX pourrait corriger l’intolérance au glucose en IRC. Nos résultats démontrent une amélioration de l’intolérance au glucose pouvant être attribuable à la moins grande réduction de l’expression protéique du GLUT4 dans les tissus périphériques et ce malgré la présence d’IRC. L’excès de PTH, secondaire à l’hyperparathyroïdie, pourrait alors être à l’origine de la résistance à l’insuline en IRC en affectant l’expression du GLUT4. L’IRC partage de nombreuses similitudes avec le prédiabète quant aux défaillances du métabolisme du glucose tout comme l’hyperinsulinémie et l’intolérance au glucose. Aucune étude n’a tenté d’évaluer si l’IRC pouvait ultimement mener au diabète. Nos résultats ont par ailleurs démontré que l’induction d’une IRC sur un modèle animal prédisposé (rats Zucker) engendrait une accentuation de leur intolérance au glucose tel que constaté par les plus hautes glycémies atteintes lors du GTT. De plus, certains d’entre eux avaient des glycémies à jeun dont les valeurs surpassent les 25 mmol/L. Il est alors possible que l’IRC puisse mener au diabète via l’évolution de la résistance à l’insuline par l’aggravation de l’intolérance au glucose. / Of all metabolic disorders found in chronic renal failure (CRF), insulin resistance remains one of the most important to consider because of the risk of morbidity and mortality it causes via cardiovascular complications. Few studies have considered the modulation of glucose transporters as the mechanism underlying the emergence and progression of insulin resistance in CRF. We explored this hypothesis by studying the expression of glucose transporters from organs involved in its homeostasis (muscle , fat , liver and kidneys) through the use of an animal model reflecting CRF (5/6th nephrectomy). The insulin sensitivity was determined by a glucose tolerance test (GTT), where the results reflect glucose intolerance and hyperinsulinemia , and transport studies in muscle show a decrease in glucose uptake in CRF ratss (~31% , p<0.05). The significant decrease in GLUT4 in peripheral tissues (~40%, p<0.001) may be the cause of insulin resistance in CRF. Furthermore, increased protein expression of the majority of glucose transporters (SGLT1, SGLT2, GLUT1, p<0.05) within the kidney in CRF causes greater glucose reabsorption in which consequential hyperglycemia promotes a decrease in GLUT4 thus exacerbating insulin resistance. Elevated protein levels of GLUT1 and GLUT2 in the liver reflects an impaired glucose homeostasis in CRF. The results show that the modulation of the expression of glucose transporters may be responsible for insulin resistance in CRF. The impact of parathyroidectomy (PTX) on the expression of GLUT4 was studied since PTX is known to correct glucose intolerance in CRF. Our results show an improvement in glucose intolerance which may be due to less reduction of GLUT4 protein expression in peripheral tissues despite the presence of CRF. The excess of PTH, linked to secondary hyperparathyroidism, could be held responsible to the presence of insulin resistance in CRF by affectant GLUT4 expression. CRF shares many similarities with prediabetes in regards to impaired glucose metabolism such as hyperinsulinemia and glucose intolerance. No studies have attempted to assess whether CRF could lead to diabetes. Our results demonstrated that the induction of CRF in a predisposed animal model (Zucker rats) provoked greater glucose intolerance as evidenced by the highest blood glucose levels reached in the GTT. In addition, some of them had fasting blood glucose levels whose values exceeded 25 mmol/L. It is therefore possible that CRF can lead to diabetes through the evolution of insulin resistance by the worsening of glucose intolerance.

Parmi l’ensemble des désordres métaboliques retrouvés en insuffisance rénale chronique (IRC), la résistance à l’insuline demeure l’un des plus importantes à considérer en raison des risques de morbidité et de mortalité qu’elle engendre via les complications cardiovasculaires. Peu d’études ont considéré la modulation de transporteurs de glucose comme mécanisme sous-jacent à l’apparition et à la progression de la résistance à l’insuline en IRC. Nous avons exploré cette hypothèse en étudiant l’expression de transporteurs de glucose issus d’organes impliqués dans son homéostasie (muscles, tissus adipeux, foie et reins) via l’utilisation d’un modèle animal d’IRC (néphrectomie 5/6e). La sensibilité à l’insuline a été déterminée par un test de tolérance au glucose (GTT), où les résultats reflètent une intolérance au glucose et une hyperinsulinémie, et par les études de transport au niveau musculaire qui témoignent d’une diminution du métabolisme du glucose en IRC (~31%; p<0,05). La diminution significative du GLUT4 dans les tissus périphériques (~40%; p<0,001) peut être à l’origine de la résistance à l’insuline en IRC. De plus, l’augmentation de l’expression protéique de la majorité des transporteurs de glucose (SGLT1, SGLT2, GLUT1; p<0,05) au niveau rénal en IRC engendre une plus grande réabsorption de glucose dont l’hyperglycémie subséquente favorise une diminution du GLUT4 exacerbant ainsi la résistance à l’insuline. L’élévation des niveaux protéiques de GLUT1 et GLUT2 au niveau hépatique témoigne d’un défaut homéostatique du glucose en IRC. Les résultats jusqu’ici démontrent que la modulation de l’expression des transporteurs de glucose peut être à l’origine de la résistance à l’insuline en IRC. L’impact de la parathyroïdectomie (PTX) sur l’expression du GLUT4 a été étudié étant donné que la PTX pourrait corriger l’intolérance au glucose en IRC. Nos résultats démontrent une amélioration de l’intolérance au glucose pouvant être attribuable à la moins grande réduction de l’expression protéique du GLUT4 dans les tissus périphériques et ce malgré la présence d’IRC. L’excès de PTH, secondaire à l’hyperparathyroïdie, pourrait alors être à l’origine de la résistance à l’insuline en IRC en affectant l’expression du GLUT4. L’IRC partage de nombreuses similitudes avec le prédiabète quant aux défaillances du métabolisme du glucose tout comme l’hyperinsulinémie et l’intolérance au glucose. Aucune étude n’a tenté d’évaluer si l’IRC pouvait ultimement mener au diabète. Nos résultats ont par ailleurs démontré que l’induction d’une IRC sur un modèle animal prédisposé (rats Zucker) engendrait une accentuation de leur intolérance au glucose tel que constaté par les plus hautes glycémies atteintes lors du GTT. De plus, certains d’entre eux avaient des glycémies à jeun dont les valeurs surpassent les 25 mmol/L. Il est alors possible que l’IRC puisse mener au diabète via l’évolution de la résistance à l’insuline par l’aggravation de l’intolérance au glucose. / Of all metabolic disorders found in chronic renal failure (CRF), insulin resistance remains one of the most important to consider because of the risk of morbidity and mortality it causes via cardiovascular complications. Few studies have considered the modulation of glucose transporters as the mechanism underlying the emergence and progression of insulin resistance in CRF. We explored this hypothesis by studying the expression of glucose transporters from organs involved in its homeostasis (muscle , fat , liver and kidneys) through the use of an animal model reflecting CRF (5/6th nephrectomy). The insulin sensitivity was determined by a glucose tolerance test (GTT), where the results reflect glucose intolerance and hyperinsulinemia , and transport studies in muscle show a decrease in glucose uptake in CRF ratss (~31% , p<0.05). The significant decrease in GLUT4 in peripheral tissues (~40%, p<0.001) may be the cause of insulin resistance in CRF. Furthermore, increased protein expression of the majority of glucose transporters (SGLT1, SGLT2, GLUT1, p<0.05) within the kidney in CRF causes greater glucose reabsorption in which consequential hyperglycemia promotes a decrease in GLUT4 thus exacerbating insulin resistance. Elevated protein levels of GLUT1 and GLUT2 in the liver reflects an impaired glucose homeostasis in CRF. The results show that the modulation of the expression of glucose transporters may be responsible for insulin resistance in CRF. The impact of parathyroidectomy (PTX) on the expression of GLUT4 was studied since PTX is known to correct glucose intolerance in CRF. Our results show an improvement in glucose intolerance which may be due to less reduction of GLUT4 protein expression in peripheral tissues despite the presence of CRF. The excess of PTH, linked to secondary hyperparathyroidism, could be held responsible to the presence of insulin resistance in CRF by affectant GLUT4 expression. CRF shares many similarities with prediabetes in regards to impaired glucose metabolism such as hyperinsulinemia and glucose intolerance. No studies have attempted to assess whether CRF could lead to diabetes. Our results demonstrated that the induction of CRF in a predisposed animal model (Zucker rats) provoked greater glucose intolerance as evidenced by the highest blood glucose levels reached in the GTT. In addition, some of them had fasting blood glucose levels whose values exceeded 25 mmol/L. It is therefore possible that CRF can lead to diabetes through the evolution of insulin resistance by the worsening of glucose intolerance.

Mit Power-to-X (PtX) wird eine Reihe von Verfahren beschrieben, die elektrische Energie in andere Kraft-, Brenn- und Grundstoffe umwandeln. Mögliche Anwendungsbereiche der strombasierten Stoffe finden sich beispielsweise im Verkehrs-, Wärme- und Industriesektor. PtX leistet damit einen wichtigen Beitrag für eine Kopplung des Verkehrs- und Energiesektors. Damit PtX einen signifikanten Anteil zum Klimaschutz leisten kann, wird als Basistechnologie die Umwandlung von erneuerbaren Energien zu grünen Wasserstoff (H2), mittels eines Elektrolyseurs, angestrebt. Für die Wettbewerbsfähigkeit von grünen H2, müssen insbesondere die Gestehungskosten gesenkt werden. Dazu werden im Bericht folgende wesentliche Einflussfaktoren identifiziert: Anlagengröße und Automatisierungsgrad der Herstellung, Anzahl der Betriebsstunden (Auslastungsgrad), Stromeinkaufspreis (aus erneuerbaren Energien), Stromnebenkosten (Steuern, Abgaben und Umlagen). Darüber hinaus spielt der Genehmigungsaufwand für die Wettbewerbsfähigkeit von Elektrolyseuren eine wichtige Rolle. Zur Optimierung dieser Einflussfaktoren in Richtung einer wirtschaftlichen und wettbewerbsfähigen Produktion von grünen H2 benennt der vorliegende Bericht verschiedene politische Handlungsempfehlungen. Grundsätzlich ist es von großer Bedeutung, ein Level-Playing-Field zu schaffen und die Energiewende konsequent voranzutreiben. Dies soll vor allem durch eine umfängliche CO2-Bepreisung aller Energieträger und einen massiven Ausbau an erneuerbaren Energien in Deutschland erfolgen. Zudem schlägt die AG 5 vor, bereits heute schon den Aufbau von zukünftigen H2-Märkten weltweit zu unterstützen. Zur Senkung der Investitions- und Stromnebenkosten empfehlen die Experten der AG 5 eine ambitionierte Umsetzung der europäischen Gesetzgebung (RED II) und die Prüfung von Beimischquoten von grünem Wasserstoff in der Wärmeversorgung. Des Weiteren spricht sich die AG 5 für eine Reduzierung von Umlagen (insbesondere der EEG-Umlage) und der Beibehaltung der Netzentgeltbefreiung aus. Ein wesentlicher Schritt zur Marktreife von grünem Wasserstoff sind Skaleneffekte bei Elektrolyseuren. Dazu muss das bereits heute bestehende Marktpotential genutzt werden. Vor allem in der Industrie und in Raffinerien bestehen große Bedarfe an H2 zur stofflichen Verwendung, die derzeit noch überwiegend durch die Dampfreformierung gedeckt werden.:1 Executive Summary 2 Ausgangslage und Zielsetzung 3 Sachstand und Fokus 4 Marktpotenzial Elektrolyse 4.1 Heutige Markte für H2 In Deutschland 4.2 Potenzielle Markte für grünen Wasserstoff 4.2.1 Warme 4.2.2 Verkehr 4.2.3 Speicher 5 Wettbewerbsfähigkeit von grünem H2 5.1 Regionale Verteilung 5.2 Transportkosten für zentrale Elektrolyse 5.3 Anwendungsfalle 5.4 Ausbaubedarf erneuerbarer Energien 6 Handlungsempfehlungen 7 Anhang 7.1 Überschlägige unverbindliche Berechnung der Transportkosten von Wasserstoff Im Gasnetz

No description available.